GAfPA “NOR-SWITCH” Paper Explores Impact of Biosimilar Switching Research

Share on facebook
Share on twitter
Share on linkedin
Data from a clinical study in Norway may soon explain the effects of switching stable patients from a biologic medicine, infliximab, to its biosimilar counterpart. But, as the Global Alliance for Patient Access argues in a new white paper, policymakers must accurately interpret what the NOR-SWITCH study will – and will not – demonstrate about the safety of switching.